Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005–2017 Joseph J. Palamar & Austin Le Human Psychopharmacology Clinical and Experimental, 2019, e2690 DOI: 10.1002/hup.2690 Abstract Objectives : This study aims to examine patterns and first mentions of reported use of new or uncommon drugs across 13 years, among nationally representative samples in the United States. Methods : Participants (ages ≥12) in the National Surveys on Drug Use and Health (2005–2017, N = 730,418) were provided opportunities to type in names of new or uncommon drugs they had ever used that were not specifically queried. We examined self‐reported [...]
Lire la suiteThe link between childhood trauma and dissociation in frequent users of classic psychedelics and dissociatives Sascha B. Thal, Judith K. Daniels & Henrik Jungaberle Journal of Substance Use, may 2019 https://doi.org/10.1080/14659891.2019.1614234 ABSTRACT Background : Childhood trauma severity is associated with the level of subsequent substance use as well as with the self-reported severity of dissociation. Classic psychedelics and dissociatives target neurotransmitter systems thought to be involved in the onset of dissociative symptoms and may evoke severe and long-lasting symptoms of depersonalization in some users. However, it is currently unclear whether drug use puts people with a history of childhood trauma at higher risk of developing [...]
Lire la suiteIntérêt de la psilocybine, de l’acide lysergique diéthylamide (LSD) et de la diméthyltryptamine (DMT) dans la dépression : une revue de la littérature THÈSE MÉDECINE SPÉCIALISÉE CLINIQUE en Psychiatrie Présentée et soutenue publiquement par Sami SERGENT le 22 février 2019 ANNÉE 2019 (2019 TOU3 1503) Directeur de thèse : Dr François MONTASTRUC JURY Monsieur le Professeur Christophe ARBUS Président Monsieur le Professeur Laurent SCHMITT Assesseur Monsieur le Professeur Nicolas FRANCHITTO Assesseur Monsieur le Docteur François MONTASTRUC Assesseur Madame le Docteur Bénédicte JULLIAN Suppléant Monsieur le Docteur Nicolas NAVARRO membre invité RESUME EN FRANÇAIS : La psilocybine, l’acide lysergique diéthylamide et la diméthyltryptamine sont des psychédéliques agonistes sérotoninergiques. Les sociétés humaines en font usages depuis [...]
Lire la suiteKetamine Promising in Cocaine Addiction Batya Swift Yasgur, MA, LSW American Journal of Psychiatry, July 05, 2019 https://doi.org/10.1176/appi.ajp.2019.18101123 A single ketamine infusion combined with mindfulness-based relapse prevention therapy (MBRP) improves abstinence and cuts cravings in cocaine-dependent adults, new research suggests. Results of a randomized control trial show that rates of abstinence were significiantly higher in patients who received ketamine plus MBRP compared to control patients. Moreover, those in the group that received ketamine were significantly less likely to experience relapse compared to control persons, and cravings were also significantly lower in the ketamine group throughout the trial. "In individuals receiving MBRP, a single ketamine infusion led to significantly greater [...]
Lire la suiteCan psychedelics be the treatment for the crisis in psychopharmacology ? Genís Ona, José Carlos Bouso ICEERS Foundation, Preprint · January 2019 DOI: 10.20944/preprints201901.0249.v1 Keywords : Mental health, psychedelics, psychopharmacology, psychiatry, innovative 1. Introduction For the past few years, we have been witnessing a crisis in the field of psychopharmacology. Generally, it takes a decade and up to a billion dollars in investment to get a drug on the market. Furthermore, the majority of new drugs are ruled out during the pre-clinical phase. Less than 20% of the selected drugs make it to Phase-III evaluation involving humans. Drug development has never been an easy task. However, [...]
Lire la suiteEDITORIAL Should addiction researchers be interested in psychedelic science ? Stephen Bright, Martin Williams & David Caldicott Australasian Professional Society on Alcohol and other Drugs, Drug and Alcohol Review, 2017 DOI: 10.1111/dar.12544 As recently noted by Strauss, Bright and Williams [1], while much of the Western world has been experiencing a renaissance in research into ‘psychedelic science’ over the past decade [2], there has been no such research conducted in Australia. In Europe and the USA, studies have been conducted into lysergic acid diethylamide (LSD) that have improved our understanding of brain function [3] and reduced existential anxiety associated with dying [4], while psilocybin-assisted psychotherapy has [...]
Lire la suiteThe psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion JAMILAH R. GEORGE, TIMOTHY I. MICHAELS, JAE SEVELIUS and MONNICA T. WILLIAMS Journal of Psychedelic Studies, 2019 DOI: 10.1556/2054.2019.015 In recent years, the study of psychedelic science has resurfaced as scientists and therapists are again exploring its potential to treat an array of psychiatric conditions, such as depression, post-traumatic stress disorder, and addiction. The scientific progress and clinical promise of this movement owes much of its success to the history of indigenous healing practices; yet the work of indigenous people, ethnic and racial minorities, women, [...]
Lire la suitePatient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain Patrick Makary, Jayesh R. Parmar, Natalie Mims, Nile M. Khanfar and Robert A. Freeman JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2019 https://doi.org/10.1080/15360288.2019.1598531 ABSTRACT The use of cannabis medications has grown in recent years for the symptomatic relief of chemotherapy-induced nausea/vomiting (CINV) and chronic pain (cancer-related and noncancer-related). As states legalize the use of cannabis, it is important for pharmacists and other health care professionals to beaware of how to counsel patients receiving prescriptions for cannabis medications. The aim of this study was to develop patient counseling guidelines [...]
Lire la suiteProspects for the Use of Cannabinoids in Oncology and Palliative Care Practice : A Review of the Evidence Tomasz Dzierżanowski Cancers, 2019, 11, 129 doi:10.3390/cancers11020129 Abstract : There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients. Their multimodal action, in spite of limited efficacy, may make them an attractive alternative, particularly in patients with multiple concomitant symptoms of mild and moderate intensity. There is evidence to indicate cannabis in the treatment of pain, spasticity, seizures, sleep disorders, nausea and vomiting, and Tourette syndrome. Although the effectiveness of cannabinoids is limited, it was [...]
Lire la suiteDeconstructing Ecstasy : The Politics Of MDMA Research Charles S. Grob Addiction Research, 2000, 8, 6, 549-588 http://dx.doi.org/10.3109/16066350008998989 What is Ecstasy? Defined by the New Webster’s Dictionary as a state of intense overpowering emotion, a condition of exultation or mental rapture induced by beauty, music, artistic creation or the contemplation of the divine, ecstasy derives etymologically from the ancient Greek ekstasis, which means flight of the soul from the body. The anthropologist, Mircea Eliade, who explored the roots of religious experience in his book Shamanism: Archaic Techniques of Ecstasy, has described the function of this intense state of mind among aboriginal peoples. Select individuals are [...]
Lire la suite